HTG2014-Section-Header-publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling Biology of neoplasia Biomarkers Bladder Cancer Blood Brain Breast Cancer Cardiovascular Disease CDKN2A mutation Cells Chemokines Circulating miRNAs Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Efficacy EMT Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Head and Neck Cancer Heart HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lupus Lymphocytes Lymphoma Melanoma Mesothelioma Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets Oral Cancer Osteoarthritis Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PFAS PIK3CA mutation Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma Sub-typing Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2021

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Denkert, C., et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol 39, 2021 (suppl 15; abstr 519) DOI: 10.1200/JCO.2021.39.15_suppl.519

View External Link

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

Loibl, S., et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 39, 2021 (suppl 15; abstr 506) DOI: 10.1200/JCO.2021.39.15_suppl.506

View External Link

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518

View External Link

Plk1 expression & efficacy of Palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03)

Guerrero-Zotano, A., et al. Plk1 expression & efficacy of Palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03). Cancer Res February 15 2021 (81) (4 Supplement) PS2-01; DOI: 10.1158/1538-7445.SABCS20-PS2-01

View External Link

2020

Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Jacobs, S. A., et al. Neratinib plus Cetuximab in Quadruple WT (KRAS, NRAS, BRAF, PIK3ca) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research 2020 NOV 17 DOI: 10.1158/1078-0432.CCR-20-1831

View External Link

Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Inaki, K., et al. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis. Abstract presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 June 22-24. Online Proceedings. Session PO.MCB09.01 Functional Genomics and Other Topics

Download pdf 1.1MB
View External Link

Comparison of HTG-edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies

O'Rourke, D., et al. Comparison of HTG-edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies. Abstract presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 June 22-24. Online Proceedings. Session PO.CL11.02 Predictive Biomarkers for Treatment Efficacy 1

Download pdf 249KB
View External Link

Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.

Moura, D. S., et al. Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study. J  Clin Oncol 38: 2020 (suppl; abstr 11546). DOI: 10.1200/JCO.2020.38.15_suppl.11546

Download jpg 6.0MB
View External Link

Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome

Kim, E., et al. Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome. J Clin Oncol 38: 2020 (suppl; abstr e17506). DOI:10.1200/JCO.2020.38.15_suppl.e17506.

View External Link

Page last updated October 21, 2021